Abstract
Introduction: The Oncotype DX breast recurrence score (RS) has been validated to predict the benefits of adjuvant chemotherapy in patients with oestrogen receptor (ER)-positive, HER2-negative breast cancer. The use of Oncotype DX for predicting chemosensitivity in the neoadjuvant setting is not well established. This systematic review aimed to determine if RS performed on core needle biopsy at diagnosis predicted complete pathological response (PCR) to neoadjuvant chemotherapy (NACT) in patients with invasive breast cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
